Introgen Therapeutics, Inc.'s ADVEXIN(R) MAA Accepted for Review by European Medicines Evaluation Agency

AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, and its subsidiary Gendux Molecular Limited, today announced that the European Medicines Agency (EMEA) has accepted for review the company’s Marketing Authrorization Application (MAA) for ADVEXIN® (p53 tumor suppressor therapy) for the treatment of recurrent, refractory squamous cell carcinoma of the head and neck. ADVEXIN is an innovative gene therapy designed to restore p53 tumor suppression that is blocked in the majority of tumors. If approved, ADVEXIN will be the first gene therapy product approved for use in Europe. Introgen and Genedux announced the submission of the ADVEXIN MAA on June 30, 2008.